Literature DB >> 6218568

Moxalactam--absorption, excretion, distribution, and metabolism.

J Shimada, Y Ueda.   

Abstract

Levels of moxalactam in serum of healthy volunteers after single intramuscular injection, slow bolus intravenous injection, or intravenous infusion were proportional to the dose given. After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose. The values for cefazolin in the same volunteers were similar to those for moxalactam. No accumulation of the drug in serum was found even after multiple intravenous injections of 1 g every 12 hr for five days. Probenecid administered orally did not significantly affect levels of moxalactam in serum or urinary recovery, an observation which suggests that renal excretion of moxalactam takes place mainly through glomerular filtration. The serum half-life (beta-phase) of moxalactam in subjects with a creatinine clearance rate of less than or equal to 10 ml/min was markedly prolonged. Concentrations of moxalactam in bile were higher than those of cefazolin in a crossover study. Concentrations in sputum were 1.84-2.11 micrograms/ml in individuals given 1 g by intravenous slow bolus injection. No active metabolite of moxalactam was detected in plasma or urine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218568     DOI: 10.1093/clinids/4.supplement_3.s569

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  6 in total

1.  Moxalactam in the treatment of typhoid fever.

Authors:  M Uwaydah; S Vartivarian; S Shatila; I Raad; H Harakeh; N T Nassar
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 4.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 6.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.